Related Experiment Video
Updated: Oct 7, 2025
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Clinical Activity and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Small
Yan-Yan Hao1,2, Yi-Peng Qiao3, Jian-De Cheng1,2
1Department of Respiratory and Critical Care Medicine, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, Shanxi, People's Republic of China.
Objective:
Anlotinib was the standard monotherapy for patients with previously treated small cell lung cancer (SCLC) in recent years. Programmed cell death protein 1 (PD-1) blockade combined with antiangiogenic targeted drugs have proved to play a synergistic action for cancer treatment clinically. Consequently, the present study was to investigate the efficacy and safety of anlotinib combined with PD-1 blockades for patients with previously treated SCLC.
Methods:
A total of 36 patients with SCLC who were treated with at least one previous systemic chemotherapy regimen participated in this study retrospectively. All the patients were administered with anlotinib plus PD-1 blockades therapy. Clinical activity was assessed according to the change of target lesion by imaging evidence and all the subjects were followed up regularly. Safety profiles were collected and documented during the treatment. Univariate analysis was carried out using Log rank test and multivariate analysis was adjusted by Cox regression analysis.
Results:
All the 36 patients with previously treated SCLC were able to have their efficacy and safety profile evaluated. The best overall response of the combination regimen showed that complete response was observed in one patient, partial response was noted in 9 patients, stable disease was reported in 19 patients, progressive disease was seen in 7 patients. Therefore, the objective response rate (ORR) of the 36 patients was 27.8% (95% CI: 14.2-45.2%), disease control rate (DCR) was 80.6% (95% CI: 64.0-91.8%). Regarding the prognostic data, the median PFS and OS of the 36 patients was 4.6 months (95% CI: 3.13-6.07) and 9.3 months (95% CI: 3.30-15.30), respectively. The most common treatment-related adverse reactions were hypertension (52.8%), fatigue (47.2%), diarrhea (38.9%), hand and foot reaction (38.9%) and dermal toxicity (33.3%). Furthermore, multivariate Cox regression analysis for PFS indicated that ECOG performance status was an independent factor to predict PFS.
Conclusion:
Anlotinib combined with PD-1 blockades regimen preliminarily demonstrated encouraging efficacy and tolerable safety for patients with previously treated SCLC. The conclusion should be validated in prospective clinical trials subsequently.
Insights
Anlotinib combined with PD-1 blockade therapy shows promising efficacy and safety in previously treated small cell lung cancer (SCLC) patients. Further prospective trials are needed to confirm these findings for SCLC treatment.
Area of Science:
- Oncology
- Immunotherapy
- Targeted Therapy
Background:
- Anlotinib is a standard monotherapy for previously treated small cell lung cancer (SCLC).
- Combining Programmed cell death protein 1 (PD-1) blockade with antiangiogenic drugs shows synergistic effects in cancer treatment.
Purpose of the Study:
- To investigate the efficacy and safety of anlotinib combined with PD-1 blockades in patients with previously treated SCLC.
Main Methods:
- Retrospective study of 36 patients with previously treated SCLC.
- All patients received anlotinib plus PD-1 blockades therapy.
- Clinical activity and safety profiles were assessed; survival data analyzed using Cox regression.
Main Results:
- Objective response rate (ORR) was 27.8%, disease control rate (DCR) was 80.6%.
- Median Progression-Free Survival (PFS) was 4.6 months, median Overall Survival (OS) was 9.3 months.
- Common adverse events included hypertension, fatigue, and diarrhea. ECOG performance status predicted PFS.
Conclusions:
- Anlotinib plus PD-1 blockades demonstrated encouraging efficacy and tolerable safety in previously treated SCLC.
- Results suggest a potential new treatment option for SCLC.
- Prospective clinical trials are recommended for validation.
More Related Videos
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
